中文摘要：

目的：研究人参皂苷Rg。在大鼠体内的药代动力学及其口服生物利用度。方法：人参皂苷Rg。分别静脉（25mg／kg）和灌胃（300mg／kg）给药后，用RP—HPLC法测定大鼠血浆中其血药浓度，数据经3P97药代动力学软件计算药代动力学参数。结果：静脉和灌胃给药后，参数分别为：AUC0→t322．70±20．78、99．76±8．91μg·h／mL，CL0．08±0．02、3．01±0．69L／（kg·h），V0．23±0．01、22．75±2．09L／kg，t1／2α 0．48±0．18、0．87±0．21h，t1/2β 19．57±2．81，18．68±2．74h，MRT16．91±0．99、8．15±1．05h^-1；口服相对生物利用度为2．58％。结论：人参皂苷风．在大鼠体内的相对生物利用度很低。

英文摘要：

Objective：To investigate the pharmacokinetics and bioavailability of ginsenoside Rg1 in rats. Methods：Ginsenoside Rg1 was oral administered or intravenous administered to each rat. The plasma concentration of ginsenoside Rg1 was estimated by RP- HPLC. 3P97 software was used to calculate pharmacokinetic parameters. Results： Main parameters of ginsenoside Rg1 after oral or intravenous administered were ：AUC→t 322. 70 ± 20. 78, 99. 76 ± 8. 91μg·h/mL, CL 0. 08 ± 0. 02, 3.01 ± 0. 69 L/（ kg· h）, V 0. 23 ±0.01,22.75 ±2.09 L/kg,t1/2α 0.48 ±0. 18,0.87 ±0.21 h,t1/2β 19.57 ±2.81,18.68 ±2.74 h,MRT6.91 ±0.99,8. 15 ±1.05 h-1, respectively. The relative oral bioavailability of ginsenoside Rg1 was 2. 5%. Conclusion： The oral bioavailability of ginsenoside Rg1 is very low.